What is the price target for ALTME stock?
9 analysts have analysed ALTME.PA and the average price target is 0.11 EUR. This implies a price increase of 48.6% is expected in the next year compared to the current price of 0.0707.
TME PHARMA NV (ALTME.PA) Forecast, Price Target & Analyst Ratings
EPA:ALTME • NL0015000YE1
Current stock price
0.0707 EUR
0 (-5.35%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TME PHARMA NV (ALTME.PA).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
€0.11
Upside
+ 48.60%
From current price of €0.07 to mean target of €0.11, Based on 9 analyst forecasts
Low
€0.10
Median
€0.11
High
€0.11
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
9 Wall Street analysts provided a forecast for the next 12 months for ALTME.PA. The average price target is 0.11 EUR. This implies a price increase of 48.6% is expected in the next year compared to the current price of 0.0707.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.44%
ALTME.PA was analyzed by 9 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about ALTME.PA.
In the previous month the buy percentage consensus was at a similar level.
ALTME.PA was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates 2025 - 2027
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 40K | 80K 100.00% | 343.33K -100.00% | N/A | 20.6K | |||||||||
| EBITDA YoY % growth | -9.9M | -5.8M 41.41% | -5.15M 18.97% | N/A 2.13% | -5.116M 12.61% | N/A -43.28% | -14.42M -132.47% | -28.84M 10.96% | -12.36M 60.78% | -5.614M 10.20% | -927K 77.92% | -12.978M -1,300.00% | 56.753M 537.30% | |
| EBIT YoY % growth | -10.12M | -6.14M 39.33% | -4.697M 22.96% | -5.047M 2.33% | 161.37K 11.90% | N/A -43.00% | -14.42M -131.27% | -28.84M 10.74% | -12.36M 59.88% | -5.665M 11.27% | -927K 78.33% | -12.978M -1,300.00% | 56.65M 536.51% | |
| Operating Margin | -25,300.00% | -7,675.00% | -1,368.01% | N/A | N/A | N/A | N/A | N/A | N/A | -27,500.00% | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -218.36 64.07% | -105.06 51.89% | 91.67 187.25% | -159.65 -274.16% | -26.78 83.23% | -22.54 15.85% | -1.02 95.48% | -0.29 71.21% | -0.03 89.47% | -0.15 -400.00% | 0.47 406.67% |
All data in EUR
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in EUR
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
53.46%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
129.06%
EBIT Next 5 Year
N/A
TME PHARMA NV / ALTME.PA Forecast FAQ
What is the expected long term growth rate for ALTME stock?
The expected long term growth rate for TME PHARMA NV (ALTME.PA) is -25.99%.